Case Report: Vision Loss Induced by Capecitabine in Patient with Preexisting Left Eyes Blind
Capecitabine is an orally administered fluoropyrimidine carbamate antineoplastic agent, widely used to treat different tumor types. Eye toxicity is not well established with this type of drug. Here, we report the case of a 57-year-old man with a low rectal cancer whose vision decreased 3 weeks after...
Main Authors: | Paul Matte, Michel Ducreux |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2023-07-01
|
Series: | Case Reports in Oncology |
Subjects: | |
Online Access: | https://beta.karger.com/Article/FullText/530402 |
Similar Items
-
Preoperative chemoradiotherapy with capecitabine and triweekly oxaliplatin versus capecitabine monotherapy for locally advanced rectal cancer: a propensity-score matched study
by: Anchuan Li, et al.
Published: (2022-07-01) -
A phase II study of neoadjuvant capecitabine, oxaliplatin, and irinotecan (XELOXIRI) in patients with locally advanced rectal cancer
by: Chu Matsuda, et al.
Published: (2023-01-01) -
Capecitabine-induced hand-foot syndrome: A pharmacogenetic study beyond DPYD
by: Mirjam de With, et al.
Published: (2023-03-01) -
Capecitabine-induced coronary artery vasospasm in a patient who previously experienced a similar episode with fluorouracil therapy
by: Uğur Nadir Karakulak, et al.
Published: (2016-02-01) -
Capecitabine-Induced Ileitis during Neoadjuvant Pelvic Radio-Chemotherapy for Locally Advanced Rectal Cancer: A Case Report with Literature Review
by: Andrea Brignoli, et al.
Published: (2023-10-01)